Monitoring anti-VEGF drugs for treatment of exudative AMD;Injections intra-vitréennes d'anti-VEGF pour la dégé nérescence maculaire liée à l'âge exsudative: Place des examens complémentaires dans les décisions de retraitement

Journal Francais d'Ophtalmologie

Volumn 30, Issue 4, 2007, Pages 330-334

  Cohen, S Y ^a   Korobelnik, J F ^b   Tadayoni, R ^c   Coscas, G ^d   Creuzot Garcher, C ^e   Devin, F ^f   Gaudric, A ^c   Mauget Faysse, M ^g   Sahel, J A ^h   Souied, E ^d   Weber, M ⁱ   Soubrane, G ^d  

^a Centre Ophtalmologique d'Imagerie et de Laser   (France)

^b HÔPITAL PELLEGRIN   (France)

^c HÔPITAL LARIBOISIÈRE   (France)

^d Clinique Ophtalmologique Universitaire   (France)

^e DIJON UNIVERSITY HOSPITAL   (France)

^f Clinique Monticelli   (France)

^g Centre Rabelais   (France)

^h FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

ⁱ NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Anti VEGF drugs; Choroidal neovascularization; Fluorescein angiography; Indocyanine green angiography; Intravitreal injection; Optical coherence tomography

Indexed keywords

EID: 34247599267     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0181-5512(07)89602-1     Document Type: Article

References (25)

1. Congdon N, O'Colmain B, Klaver CC, Klein R, Munoz B, Friedman DS, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol, 2004;122:477-85.
2. Ferris FL III, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol, 1984;102:1640-2.
3. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA, 2004;291:1900-1.
4. Argon laser photocoagulation for neovascular maculopathy. Fiveyear results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol, 1991;109:1109-14.
5. Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol, 1994;112:500-9.
6. Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol, 2001;119:198-207.
7. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol, 2001;131:541-60.
8. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR, for the VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med, 2004;351(27):2805-16.
9. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group; Chakravarthy U, Adamis AP, Cunningham ET Jr, Goldbaum M, Guyer DR, Katz B, et al. Year 2 Efficacy Results of 2 Randomized Controlled Clinical Trials of Pegaptanib for Neovascular Age-Related Macular Degeneration. Ophthalmology, 2006;113:1508 [e1-25].
10. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med, 2006;355:1419-31.
11. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med, 2006;355:1432-44.
12. Kaiser RS, Berger JW, Williams GA, Tolentino MJ, Maguire AM, Alexander J, et al. Variability in fluorescein angiography interpretation for photodynamic therapy in age-related macular degeneration. Retina, 2002;22:683-90.
13. Coscas G, Coscas F, Soubrane G. La surveillance du patient après traitement. Aspects angiographiques des récidives et indications des retraitements. J Fr Ophtalmol, 2004;27:81-92.
14. Coscas G, Coscas F, Zourdani A. Atlas d'angiographie en indocyanine. Bull Soc Ophtal Fr, 2004;CIV:1-384.
15. Eter N, Spaide RF. Comparison of fluorescein angiography and optical coherence tomography for patients with choroidal neovascularization after photodynamic therapy. Retina, 2005;25:691-6.
16. Salinas-Alaman A, Garcia-Layana A, Maldonado MJ, Sainz-Gomez C, Alvarez-Vidal A. Using optical coherence tomography to monitor photodynamic therapy in age related macular degeneration. Am J Ophthalmol, 2005;140:23-8.
17. van Velthoven ME, de Smet MD, Schlingemann RO, Magnani M, Verbraak FD. Added value of OCT in evaluating the presence of leakage in patients with age-related macular degeneration treated with PDT. Graefes Arch Clin Exp Ophthalmol, 2006;244:1119-23.
18. van de Moere A, Sandhu SS, Talks SJ. Correlation of optical coherence tomography and fundus fluorescein angiography following photodynamic therapy for choroidal neovascular membranes. Br J Ophthalmol, 2006;90:304-6.
19. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging, 2005;36:331-5.
20. Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA Jr, Scott IU. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci, 2006;47:4569-78.
21. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol, 2006;142:1-9.
22. Korobelnik JF, Cochereau I, Cohen SY, Coscas G, Creuzot-Garcher C, Devin F. et al. Description des pratiques pour la réalisation des injections intravitréennes. J Fr Ophtalmol, 2006;29:82-6.
23. Coscas G, Coscas F, Soubrane G. Traitement par injection intravitréenne de Ranibizumab (Lucentis®) pour des néovaisseaux choroïdiens occultes prédominants liés à la DMLA. Étude et suivi par imagerie en fluorescéine, infracyanine et OCT pendant 6 mois. J Fr Ophtalmol, 2006;29:731-7.
24. th annual meeting of the EVRS. 10 Sept. 2006
25. Stone EM. A very effective treatment for neovascular macular degeneration. N Engl J Med, 2006;355:1493-5.